Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Malignant Melanoma : Update Bulletin [April 2015]

Product Code:
596200391
Release Date:
April 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Malignant Melanoma. Topics covered: CheckMate 069 data, KEYNOTE-006 trial, Yervoy, combination of Opdivo with Yervoy, T-VEC’s role within the treatment paradigm, Amgen’s Phase II study, Roche’s new BRAF/MEK inhibitor combination Zelboraf/cobimetinib, revision to the NCCN guidelines.

Key Questions Answered in this Update Bulletin:

  • How do KOLs view the CheckMate 069 data and do they think that a combination of Opdivo with Yervoy will be superior to Yervoy alone?
  • Will the success of the KEYNOTE-006 trial impact the first-line treatment of advanced melanoma patients?
  • Will Yervoy provide a much needed new treatment option, and replace interferon-alfa, if it is approved in the adjuvant setting for stage III melanoma?
  • Do KOLs think the combination of Opdivo with Yervoy will be more effective than Opdivo monotherapy for treating melanoma metastatic to the brain?
  • How extensive will T-VEC’s role within the treatment paradigm for malignant melanoma be if it is approved?
  • To what extent will Amgen’s Phase II study help to establish a role for T-VEC as a neo-adjuvant treatment?
  • Can Roche’s new BRAF/MEK inhibitor combination, Zelboraf/cobimetinib, provide any advantages over GlaxoSmithKline’s Tafinlar/Mekinist?
  • Will the revision to the NCCN guidelines, recommending first-line use of Keytruda and Opdivo, impact physician prescribing?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved